Compare DSP Healthcare Fund vs SBI Healthcare Opportunities Fund
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.93 | 1.93 |
NAV | ₹37.70 | ₹403.64 |
Fund Started | 12 Nov 2018 | 04 Jun 1999 |
Fund Size | ₹3114.33 Cr | ₹3989.42 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
4.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.93
1.93
NAV
₹37.70
₹403.64
Fund Started
12 Nov 2018
04 Jun 1999
Fund Size
₹3114.33 Cr
₹3989.42 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
1 Year | -4.95% | -0.86% |
3 Year | 20.42% | 22.82% |
5 Year | 14.48% | 15.48% |
1 Year
-4.95%
-0.86%
3 Year
20.42%
22.82%
5 Year
14.48%
15.48%
Equity | 98.20% | 96.59% |
Cash | 1.80% | 3.34% |
Equity
98.20%
96.59%
Cash
1.80%
3.34%
Top 10 Holdings |
|
|
Top 10 Holdings
Cipla Ltd. | 8.69% |
Sun Pharmaceutical Industries Ltd. | 8.48% |
Ipca Laboratories Ltd. | 7.73% |
Globus Medical Inc | 6.78% |
Laurus Labs Ltd. | 6.52% |
Illumina Inc. (USA) | 6.07% |
Sai Life Sciences Ltd. | 5.23% |
Gland Pharma Ltd. | 5.09% |
Cohance Lifesciences Ltd. | 5.04% |
Apollo Hospitals Enterprise Ltd. | 4.40% |
Sun Pharmaceutical Industries Ltd. | 11.64% |
Divi's Laboratories Ltd. | 7.05% |
Max Healthcare Institute Ltd. | 5.24% |
Lupin Ltd. | 4.44% |
Laurus Labs Ltd. | 3.89% |
Torrent Pharmaceuticals Ltd. | 3.86% |
Acutaas Chemicals Ltd. | 3.85% |
Cipla Ltd. | 3.79% |
Lonza Group Ag | 3.63% |
Biocon Ltd. | 3.16% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 12 Nov 2018 | 04 Jun 1999 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
12 Nov 2018
04 Jun 1999